- 03.02.2010, 07:01:32
- /
- OTE0001
Daiichi Sankyo initiates largest single, double-blind, randomized, Phase III trial for treatment and prevention of recurrent venous thromboembolism
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | EUN
